Study of Recombinant Human N-Acetylgalactosamine 4-Sulfatase in Patients With MPS VI
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety, efficacy and pharmacokinetics of two dose
levels of weekly intravenous infusions of recombinant human N-acetylgalactosamine 4-sulfatase
(rhASB) for a minimum of 24 weeks in patients diagnosed with MPS VI.